CRISPR Therapeutics AG (CRSP)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about CRISPR Therapeutics AG (CRSP)
Go deeper and ask any question about CRSP
Company Performance
Current Price
as of Sep 13, 2024$48.94
P/E Ratio
N/A
Market Cap
$4.17B
Description
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Metrics
Overview
- HQZug, ZG
- SectorHealth Technology
- IndustryBiotechnology
- TickerCRSP
- Price$48.94+6.65%
Trading Information
- Market Cap$4.17B
- Float95.66%
- Average Daily Volume (1m)891,247
- Average Daily Volume (3m)1,219,854
- EPS-$3.20
Company
- Revenue$202.23M
- Rev Growth (1yr)-99.26%
- Net Income-$126.41M
- Gross Margin-10,920.50%
- EBITDA Margin-28,320.12%
- EBITDA-$146.42M
- EV$2.82B
- EV/Revenue13.93
- P/EN/A
- P/S20.55